Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06545136 · ClinicalTrials.gov registry record · Phase 1
Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)
A Phase 1 study of Gaucher Disease, Type 1, sponsored by Spur Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 4
- Study locations
NCT06545136 is a Phase 1 study of Gaucher Disease, Type 1 that is active but no longer recruiting, run by Spur Therapeutics. The registered enrollment target is 75 participants, above the 50-participant average among 8 other Gaucher Disease, Type 1 trials with a reported enrollment target (50% higher). The trial reports 4 study locations across 2 states.
The verdict
NCT06545136, a Phase 1 study of Gaucher Disease, Type 1, is active but no longer recruiting, sponsored by Spur Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a multicenter, long-term, follow-up trial of participants with Gaucher disease type 1 who received FLT201 treatment in a preceding clinical trial. Participants will be followed for 5 years post-treatment.
Conditions Studied
Interventions
- GENETIC FLT201
Study Locations (4)
Other
- Hospital de Clinicas de Porto Alegre (HCPA) - Porto Alegre
- Hospital Quironsalud Zaragoza - Zaragoza
- Salford Royal Hospital - Salford
Virginia
- Lysosomal Rare Disorders Research and Treatment Center - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2024-05-13 |
| Est. Completion | 2029-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06545136
The ClinicalTrials.gov registry entry for NCT06545136 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 50-participant average among 8 other Gaucher Disease, Type 1 trials with a reported enrollment target (50% higher). The listed sponsor is Spur Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gaucher Disease, Type 1 appearing as the primary indexed condition, and to 1 intervention - of which FLT201 is the first listed.
NCT06545136 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Other, Virginia.
Frequently Asked Questions
What is clinical trial NCT06545136 about?
NCT06545136 is a clinical study titled "Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)". This is a multicenter, long-term, follow-up trial of participants with Gaucher disease type 1 who received FLT201 treatment in a preceding clinical trial. Participants will be followed for 5 years post-treatment.
What is the current status of trial NCT06545136?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2024-05-13. Estimated completion is 2029-05.
What conditions does trial NCT06545136 study?
This clinical trial studies the following conditions: Gaucher Disease, Type 1.
What interventions are being tested in trial NCT06545136?
The interventions under investigation include: FLT201 (GENETIC).
Who is sponsoring clinical trial NCT06545136?
This trial is sponsored by Spur Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06545136 being conducted?
This trial has 4 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gaucher Disease, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
RECRUITING · Phase 1
-
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension
ACTIVE NOT RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients
COMPLETED · Phase 2
-
A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy
COMPLETED · Phase 2
-
A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease
COMPLETED · Phase 2
-
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.